Palmoplantar Keratoderma (PPK) Market
[170+ Pages Research Report] Palmoplantar Keratoderma (PPK) Market treach USD 1,458.8 Million by 2030 from USD 1,098.9 Million in 2020 at a CAGR of 2.87% in the coming years, i.e., 2021-30.
Product Overview
Palmoplantar keratodermas (PPK) is a group of illnesses characterized by the thickening of the skin on the palms and soles of affected individuals' feet. PPK can be classified intdifferent categories such as hereditary forms with only skin complications, hereditary syndromes with PPK as an associated feature, and acquired forms. Hereditary PPK is the most common form of PPK which is generally diagnosed in the affected patients. Hereditary forms can be limited tthe hands and feet, or they might be linked ta more widespread skin condition. Genetic mutations produce inherited PPKs, which result in keratin (a skin protein) abnormalities. Autosomal dominant or autosomal recessive inheritance can occur depending on the genetic reason. Acquired PPKs, on the other hand, might occur as a result of changes in a person's health or surroundings.
Market Highlights
Global Palmoplantar Keratoderma (PPK) Market is expected tproject a notable CAGR of 2.87% in 2030.
Global Palmoplantar Keratoderma (PPK) Market is anticipated twitness lucrative growth opportunities in the coming years. Rising prevalence of PPK across the 7MM has triggered health concerns among the economies. Governments across the 7MM are increasing funding and grants for research and development activities for the production & invention of new medicines tdevelop new therapies which is proliferating the growth of the PPK market.
Market Dynamics
Drivers
Persistent research & development towards understanding the pathophysiology
Across the globe organizations are consistently working towards understanding the pathophysiology of Palmoplantar Keratoderma (PPK). Few clinical trials initiated for the treatment of Palmoplantar Keratoderma namely; SGT-210 (Sol-Gel) and others. Sol-Gel is a dermatology company that is investigating its product SGT-210. It is the epidermal growth factor receptor (EGFR) inhibitor, which is administered topically. For Instance, EGFR induces cell differentiation and proliferation upon activation through the binding of one of its ligands. This product is targeting patients with punctate palmoplantar keratoderma type -1 (PPPK type 1).
This product is in Phase I proof of concept clinical study. Nevertheless, the lack of key players in this horizon is quite evident. Due tthis, there is a wide scope thave a large share in the total market size of the PPK in the seven major markets.
Increasing investments in healthcare infrastructural development
Palmoplantar Keratoderma (PPK) is a rare disease and presently there is navailable curative and specific therapy. This drives the growth of the market due trising need and demand for certain therapy and treatment of the disease. Also, increasing efforts by the pharmaceutical and biotechnology companies along with the research laboratories focused towards the development of new drugs and therapies are contributing tthe double-digit growth of the market in 7MM. Moreover, the growth of the palmoplantar keratoderma market is driven by increasing healthcare expenditure and growing R&D activities.
Restraint
Stringent rules & regulations
Governments across the 7MM have implemented numerous stringent rules and regulations relating tthe clinical trial for the drugs of PPK, which are significantly hampering the PPK market in the 7MM. For instance, there is potential adverse federal, state and local government regulation in the United States.
Global Palmoplantar Keratoderma (PPK) Market: Key Players
Cilas, Murata Manufacturing Co.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Ltd., Ceranova Corporation
Brightcrystals Technology Inc.
Ceramtec-Etec GmbH
Coorstek, Inc.
Konoshima Chemicals Co.Ltd.
Surmet Corporation
Schott AG
II-VI Optical Systems
Advanced Ceramic Manufacturing
LLC
Other Prominent Players
Global Palmoplantar Keratoderma (PPK) Market: Regions
Global Palmoplantar Keratoderma (PPK) Market is segmented based on regional analysis intfive major regions. These include North America, Latin America, Europe, Asia Pacific and the Middle East and Africa.
As per our estimates, In the United States, the availability of coverage and adequate reimbursement from third-party payors is a factor in the sale of any product that have received regulatory approval for commercial sale. Government agencies and health programs, such as Medicare and Medicaid, as well as managed care providers, private health insurers, and other organizations, are examples of third-party payors. Pricing and reimbursement schemes in the EU vary significantly from nation tnation. Some governments stipulate that the companies can only sell their products if a reimbursement price has been agreed upon. Additional research comparing the cost-effectiveness of a given product talready available therapies is might be required in some regions.
Global Palmoplantar Keratoderma (PPK) Market is further segmented by region into:
U.S. Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
MexicMarket Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Germany Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
France Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Italy Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Spain Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
U.K. Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Japan Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Global Palmoplantar Keratoderma (PPK) Market report alscontains analysis on:
Palmoplantar Keratoderma (PPK) Market Dynamics
Palmoplantar Keratoderma (PPK) Market Size
Supply & Demand
Market Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
Product Overview
Palmoplantar keratodermas (PPK) is a group of illnesses characterized by the thickening of the skin on the palms and soles of affected individuals' feet. PPK can be classified intdifferent categories such as hereditary forms with only skin complications, hereditary syndromes with PPK as an associated feature, and acquired forms. Hereditary PPK is the most common form of PPK which is generally diagnosed in the affected patients. Hereditary forms can be limited tthe hands and feet, or they might be linked ta more widespread skin condition. Genetic mutations produce inherited PPKs, which result in keratin (a skin protein) abnormalities. Autosomal dominant or autosomal recessive inheritance can occur depending on the genetic reason. Acquired PPKs, on the other hand, might occur as a result of changes in a person's health or surroundings.
Market Highlights
Global Palmoplantar Keratoderma (PPK) Market is expected tproject a notable CAGR of 2.87% in 2030.
Global Palmoplantar Keratoderma (PPK) Market is anticipated twitness lucrative growth opportunities in the coming years. Rising prevalence of PPK across the 7MM has triggered health concerns among the economies. Governments across the 7MM are increasing funding and grants for research and development activities for the production & invention of new medicines tdevelop new therapies which is proliferating the growth of the PPK market.
Market Dynamics
Drivers
Persistent research & development towards understanding the pathophysiology
Across the globe organizations are consistently working towards understanding the pathophysiology of Palmoplantar Keratoderma (PPK). Few clinical trials initiated for the treatment of Palmoplantar Keratoderma namely; SGT-210 (Sol-Gel) and others. Sol-Gel is a dermatology company that is investigating its product SGT-210. It is the epidermal growth factor receptor (EGFR) inhibitor, which is administered topically. For Instance, EGFR induces cell differentiation and proliferation upon activation through the binding of one of its ligands. This product is targeting patients with punctate palmoplantar keratoderma type -1 (PPPK type 1).
This product is in Phase I proof of concept clinical study. Nevertheless, the lack of key players in this horizon is quite evident. Due tthis, there is a wide scope thave a large share in the total market size of the PPK in the seven major markets.
Increasing investments in healthcare infrastructural development
Palmoplantar Keratoderma (PPK) is a rare disease and presently there is navailable curative and specific therapy. This drives the growth of the market due trising need and demand for certain therapy and treatment of the disease. Also, increasing efforts by the pharmaceutical and biotechnology companies along with the research laboratories focused towards the development of new drugs and therapies are contributing tthe double-digit growth of the market in 7MM. Moreover, the growth of the palmoplantar keratoderma market is driven by increasing healthcare expenditure and growing R&D activities.
Restraint
Stringent rules & regulations
Governments across the 7MM have implemented numerous stringent rules and regulations relating tthe clinical trial for the drugs of PPK, which are significantly hampering the PPK market in the 7MM. For instance, there is potential adverse federal, state and local government regulation in the United States.
Global Palmoplantar Keratoderma (PPK) Market: Key Players
Cilas, Murata Manufacturing Co.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Ltd., Ceranova Corporation
Brightcrystals Technology Inc.
Ceramtec-Etec GmbH
Coorstek, Inc.
Konoshima Chemicals Co.Ltd.
Surmet Corporation
Schott AG
II-VI Optical Systems
Advanced Ceramic Manufacturing
LLC
Other Prominent Players
Global Palmoplantar Keratoderma (PPK) Market: Regions
Global Palmoplantar Keratoderma (PPK) Market is segmented based on regional analysis intfive major regions. These include North America, Latin America, Europe, Asia Pacific and the Middle East and Africa.
As per our estimates, In the United States, the availability of coverage and adequate reimbursement from third-party payors is a factor in the sale of any product that have received regulatory approval for commercial sale. Government agencies and health programs, such as Medicare and Medicaid, as well as managed care providers, private health insurers, and other organizations, are examples of third-party payors. Pricing and reimbursement schemes in the EU vary significantly from nation tnation. Some governments stipulate that the companies can only sell their products if a reimbursement price has been agreed upon. Additional research comparing the cost-effectiveness of a given product talready available therapies is might be required in some regions.
Global Palmoplantar Keratoderma (PPK) Market is further segmented by region into:
U.S. Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
MexicMarket Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Germany Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
France Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Italy Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Spain Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
U.K. Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Japan Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
Global Palmoplantar Keratoderma (PPK) Market report alscontains analysis on:
Palmoplantar Keratoderma (PPK) Market Dynamics
Palmoplantar Keratoderma (PPK) Market Size
Supply & Demand
Market Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
1. REPORT INTRODUCTION
1.1. Introduction
1.1.1. Scope of Study
2. EXECUTIVE SUMMARY
3. SWOT ANALYSIS
3.1. Overview
4. DISEASE BACKGROUND AND OVERVIEW
4.1. Introduction
4.1.1. Diffuse Hereditary PPK:
4.1.2. Focal and Striate Hereditary PPK
4.1.3. Punctate Hereditary PPK
4.2. Causes
4.3. Pathophysiology
4.4. Risks and Symptoms
4.5. Diagnosis
5. COUNTRY-SPECIFIC PATIENT POPULATION OF PALMOPLANTAR KERATODERMA
5.1. United States
6. MEXICO
6.1. Europe
6.2. Asia-Pacific
7. JAPAN
7.1. Current Treatment and Medical Practices
8. PATIENTS JOURNEY
9. UNMET NEEDS
9.1. Overview
10. PALMOPLANTAR KERATODERMA: MARKET SIZE ANALYSIS
11. COUNTRY-WISE MARKET ANALYSIS
11.1. United States
11.2. Mexico
11.3. Germany
11.4. France
11.5. Italy
11.6. Spain
11.7. United Kingdom
11.8. Japan
12. MARKET ACCESS AND REIMBURSEMENT OF PPK
12.1. Overview
12.1.1. United States
12.1.2. Europe
12.1.3. Japan
13. MARKET BARRIERS
13.1. Overview
13.1.1. Scarcity of clinical trials and absence of information
13.1.2. Stringent rules & regulations
13.1.3. High cost involved in research and development
14. MARKET DRIVERS
14.1. Overview
14.1.1. Persistent research & development towards understanding the pathophysiology
14.1.2. Increasing investments in healthcare infrastructural development
14.1.3. Rise in prevalent cases of chronic patients
14.1.4. Government initiatives
15. ATTRIBUTE ANALYSIS
15.1. Overview
16. APPENDIX
16.1. List of Abbreviations
17. RESEARCH METHODOLOGY
17.1. Research Objective
17.2. Research Approach
17.3. Data Sourcing and Methodology
17.4. Secondary Research
17.5. Market Size Estimation and Data Triangulation
18. DISCLAIMER
1.1. Introduction
1.1.1. Scope of Study
2. EXECUTIVE SUMMARY
3. SWOT ANALYSIS
3.1. Overview
4. DISEASE BACKGROUND AND OVERVIEW
4.1. Introduction
4.1.1. Diffuse Hereditary PPK:
4.1.2. Focal and Striate Hereditary PPK
4.1.3. Punctate Hereditary PPK
4.2. Causes
4.3. Pathophysiology
4.4. Risks and Symptoms
4.5. Diagnosis
5. COUNTRY-SPECIFIC PATIENT POPULATION OF PALMOPLANTAR KERATODERMA
5.1. United States
6. MEXICO
6.1. Europe
6.2. Asia-Pacific
7. JAPAN
7.1. Current Treatment and Medical Practices
8. PATIENTS JOURNEY
9. UNMET NEEDS
9.1. Overview
10. PALMOPLANTAR KERATODERMA: MARKET SIZE ANALYSIS
11. COUNTRY-WISE MARKET ANALYSIS
11.1. United States
11.2. Mexico
11.3. Germany
11.4. France
11.5. Italy
11.6. Spain
11.7. United Kingdom
11.8. Japan
12. MARKET ACCESS AND REIMBURSEMENT OF PPK
12.1. Overview
12.1.1. United States
12.1.2. Europe
12.1.3. Japan
13. MARKET BARRIERS
13.1. Overview
13.1.1. Scarcity of clinical trials and absence of information
13.1.2. Stringent rules & regulations
13.1.3. High cost involved in research and development
14. MARKET DRIVERS
14.1. Overview
14.1.1. Persistent research & development towards understanding the pathophysiology
14.1.2. Increasing investments in healthcare infrastructural development
14.1.3. Rise in prevalent cases of chronic patients
14.1.4. Government initiatives
15. ATTRIBUTE ANALYSIS
15.1. Overview
16. APPENDIX
16.1. List of Abbreviations
17. RESEARCH METHODOLOGY
17.1. Research Objective
17.2. Research Approach
17.3. Data Sourcing and Methodology
17.4. Secondary Research
17.5. Market Size Estimation and Data Triangulation
18. DISCLAIMER
